Pharmaceutical

Agios sells vorasidenib US royalties for $905m

Royalty Pharma will receive 15% on US sales of vorasidenib, up to $1bn, and at a 12% rate beyond that.

May 31, 2024 - 04:00
Agios sells vorasidenib US royalties for $905m
Royalty Pharma will receive 15% on US sales of vorasidenib, up to $1bn, and at a 12% rate beyond that.
Read the original article

Tags:

Previous Article

Sanofi completes the $1.7bn acquisition of Inhibrx

Next Article

Gilead urged to improve access to HIV drug by public figures and celebrities

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Many immigrants are ineligible for important U.S. maternal health initiatives

Opinion: Many immigrants are ineligible for important U...

Jul 28, 2023

STAT+: In Silicon Valley, a venture capital firm gives health tech startups a crash course in getting paid

STAT+: In Silicon Valley, a venture capital firm gives ...

May 15, 2023

Innovation in immuno-oncology: Leading companies in monoclonal antibody conjugates for cancer treatment

Innovation in immuno-oncology: Leading companies in mon...

May 8, 2023